Albany Molecular Research Company Profile (NASDAQ:AMRI)

About Albany Molecular Research

Albany Molecular Research logoAlbany Molecular Research, Inc. is a global contract research and manufacturing company. The Company provides drug discovery, development, and manufacturing services. The Company operates through three segments: Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API) and Drug Product Manufacturing (DPM). The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small-scale commercial manufacturing. API includes pilot to commercial scale manufacturing of active pharmaceutical ingredients and intermediates and high potency and controlled substance manufacturing. DPM includes pre-formulation, formulation and process development through commercial scale production of complex liquid-filled and lyophilized injectable formulations. It supplies a range of services and technologies supporting the discovery and development of pharmaceutical products, the manufacturing of API and drug product for new and generic drugs.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: AMRI
  • CUSIP:
Key Metrics:
  • Previous Close: $18.67
  • 50 Day Moving Average: $18.44
  • 200 Day Moving Average: $16.73
  • 52-Week Range: $41,590,000.00 - $12.45
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 14.32
  • P/E Growth: 1.54
  • Market Cap: $798.20B
  • Outstanding Shares: 41,590,000
  • Beta: 1.26
  • Net Margins: -10.48%
  • Return on Equity: 7.25%
  • Return on Assets: 2.26%
  • Debt-to-Equity Ratio: 1.79%
  • Current Ratio: 2.21%
  • Quick Ratio: 1.11%
Additional Links:
Companies Related to Albany Molecular Research:

Analyst Ratings

Consensus Ratings for Albany Molecular Research (NASDAQ:AMRI) (?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $17.00 (8.65% downside)

Analysts' Ratings History for Albany Molecular Research (NASDAQ:AMRI)
DateFirmActionRatingPrice TargetDetails
8/5/2016Morgan StanleyReiterated RatingBuy$17.00View Rating Details
10/26/2015First AnalysisUpgradeEqual Weight -> Overweight$25.00View Rating Details
(Data available from 2/19/2015 forward)


Earnings History for Albany Molecular Research (NASDAQ:AMRI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/21/2017Q416$0.48$221.30 millionN/AView Earnings Details
11/8/2016Q316$0.13$0.17$160.75 million$151.70 millionViewListenView Earnings Details
5/10/2016Q1$0.21$0.07$107.20 million$102.80 millionViewListenView Earnings Details
2/17/2016Q415$0.36$0.40$133.40 million$126.40 millionViewListenView Earnings Details
11/5/2015Q315$0.11$0.11$95.15 million$101.40 millionViewListenView Earnings Details
8/4/2015Q215$0.18$0.22$85.00 million$85.20 millionViewListenView Earnings Details
5/5/2015Q115$0.15$0.20$81.50 million$75.10 millionViewN/AView Earnings Details
2/12/2015Q414$0.33$0.28$91.90 million$86.60 millionViewN/AView Earnings Details
11/5/2014$0.16($0.02)ViewN/AView Earnings Details
8/5/2014Q214$0.20$0.22$65.64 million$68.20 millionViewN/AView Earnings Details
5/6/2014Q114$0.23$0.16$62.19 million$51.00 millionViewN/AView Earnings Details
2/12/2014Q4$0.17$0.22ViewN/AView Earnings Details
11/6/2013Q313$0.11$0.13$62.10 million$53.00 millionViewN/AView Earnings Details
8/6/2013Q2 2013$0.12$50.00 million$59.30 millionViewN/AView Earnings Details
5/7/2013Q1 2013$0.10$0.23$53.70 million$59.40 millionViewN/AView Earnings Details
2/12/2013Q4 2012$0.09$0.17$56.49 million$59.10 millionViewN/AView Earnings Details
8/1/2012$0.02$0.01ViewN/AView Earnings Details
5/9/2012$0.05$0.02ViewN/AView Earnings Details
2/7/2012($0.12)($0.19)ViewN/AView Earnings Details
11/8/2011($0.05)($0.19)ViewN/AView Earnings Details
8/8/2011($0.03)($0.02)ViewN/AView Earnings Details
5/4/2011($0.14)($0.02)ViewN/AView Earnings Details
2/7/2011($0.15)($0.16)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Albany Molecular Research (NASDAQ:AMRI)
Current Year EPS Consensus Estimate: $1.08 EPS
Next Year EPS Consensus Estimate: $1.30 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161$0.33$0.33$0.33
Q3 20161$0.13$0.13$0.13
Q4 20161$0.48$0.48$0.48
Q1 20171$0.22$0.22$0.22
Q2 20171$0.35$0.35$0.35
Q3 20171$0.19$0.19$0.19
(Data provided by Zacks Investment Research)


Dividend History for Albany Molecular Research (NASDAQ:AMRI)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Albany Molecular Research (NASDAQ:AMRI)
Insider Ownership Percentage: 17.50%
Institutional Ownership Percentage: 72.07%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/2/2016Anthony J MaddalunaDirectorBuy1,518$16.46$24,986.28View SEC Filing  
11/30/2016Steven R HagenSVPSell9,000$16.71$150,390.00View SEC Filing  
11/16/2016Lori M HendersonSVPSell6,000$17.00$102,000.00View SEC Filing  
11/10/2016Steven R HagenSVPSell785$16.79$13,180.15View SEC Filing  
8/9/2016Steven R HagenSVPSell1,401$15.29$21,421.29View SEC Filing  
5/31/2016Kevin OconnorDirectorSell5,000$14.41$72,050.00View SEC Filing  
5/16/2016William S MarthCEOBuy12,500$12.86$160,750.00View SEC Filing  
5/13/2016George SvokosCOOBuy12,500$12.82$160,250.00View SEC Filing  
5/13/2016Steven R HagenSVPSell2,361$12.77$30,149.97View SEC Filing  
11/9/2015Ambra Constance M DMajor ShareholderSell50,000$19.60$980,000.00View SEC Filing  
8/17/2015Steven R HagenSVPSell1,000$20.45$20,450.00View SEC Filing  
6/10/2015Ambra Constance M DMajor ShareholderSell20,000$19.77$395,400.00View SEC Filing  
6/8/2015Steven R HagenSVPSell5,000$19.99$99,950.00View SEC Filing  
6/4/2015William S MarthCEOBuy10,000$19.98$199,800.00View SEC Filing  
6/1/2015Stuart M CableMajor ShareholderSell30,000$19.69$590,700.00View SEC Filing  
5/11/2015Ambra Constance M DMajor ShareholderSell20,000$19.11$382,200.00View SEC Filing  
5/8/2015Steven R HagenSVPSell14,500$19.27$279,415.00View SEC Filing  
4/10/2015Ambra Constance M DMajor ShareholderSell20,000$18.50$370,000.00View SEC Filing  
3/17/2015Steven R HagenSVPSell3,500$18.53$64,855.00View SEC Filing  
3/12/2015Kevin OconnorDirectorSell5,000$18.22$91,100.00View SEC Filing  
3/10/2015Ambra Thomas E Phd DDirectorSell20,000$17.65$353,000.00View SEC Filing  
3/10/2015George SvokosInsiderBuy10,000$17.72$177,200.00View SEC Filing  
3/5/2015William S MarthCEOBuy20,000$17.70$354,000.00View SEC Filing  
3/2/2015Stuart M CableMajor ShareholderSell30,000$16.39$491,700.00View SEC Filing  
2/10/2015Ambra Thomas E Phd DDirectorSell20,000$16.91$338,200.00View SEC Filing  
2/2/2015Stuart M CableMajor ShareholderSell30,000$16.32$489,600.00View SEC Filing  
1/12/2015Ambra Thomas E Phd DDirectorSell20,000$16.45$329,000.00View SEC Filing  
1/7/2015Stuart M CableMajor ShareholderSell7,694$16.00$123,104.00View SEC Filing  
1/5/2015Stuart M CableMajor ShareholderSell22,306$16.21$361,580.26View SEC Filing  
12/10/2014Ambra Constance M DMajor ShareholderSell20,000$16.24$324,800.00View SEC Filing  
12/5/2014Stuart M CableMajor ShareholderSell13,307$16.00$212,912.00View SEC Filing  
12/4/2014Stuart M CableMajor ShareholderSell16,693$16.00$267,088.00View SEC Filing  
11/10/2014William S MarthCEOBuy30,000$17.01$510,300.00View SEC Filing  
10/10/2014Ambra Constance M DMajor ShareholderSell20,000$21.62$432,400.00View SEC Filing  
10/1/2014Lori M HendersonSVPSell1,000$21.48$21,480.00View SEC Filing  
10/1/2014Stuart M CableMajor ShareholderSell30,000$21.61$648,300.00View SEC Filing  
9/10/2014Ambra Constance M DMajor ShareholderSell20,000$20.12$402,400.00View SEC Filing  
9/2/2014Lori M HendersonSVPSell2,500$19.56$48,900.00View SEC Filing  
8/28/2014Steven R HagenSVPSell1,250$19.74$24,675.00View SEC Filing  
8/14/2014Michael M NolanCFOSell10,000$19.76$197,600.00View SEC Filing  
8/12/2014Lori M HendersonSVPSell30,000$19.05$571,500.00View SEC Filing  
8/11/2014Ambra Thomas E Phd DDirectorSell20,000$18.99$379,800.00View SEC Filing  
8/8/2014Steven R HagenSVPSell10,797$18.99$205,035.03View SEC Filing  
8/1/2014Lori M HendersonSVPSell2,500$18.56$46,400.00View SEC Filing  
8/1/2014Stuart M CableMajor ShareholderSell30,000$18.69$560,700.00View SEC Filing  
7/10/2014Ambra Thomas E Phd DDirectorSell20,000$20.94$418,800.00View SEC Filing  
7/1/2014Lori M HendersonSVPSell2,500$20.62$51,550.00View SEC Filing  
7/1/2014Stuart M CableMajor ShareholderSell30,000$21.00$630,000.00View SEC Filing  
6/3/2014Steven R HagenSVPSell2,500$16.93$42,325.00View SEC Filing  
5/16/2014Steven HagenSVPSell1,250$15.45$19,312.50View SEC Filing  
5/15/2014George SvokosSVPBuy10,000$15.60$156,000.00View SEC Filing  
5/12/2014Steven HagenSVPSell5,897$15.00$88,455.00View SEC Filing  
5/12/2014William MarthCEOBuy30,000$15.40$462,000.00View SEC Filing  
5/1/2014Lori HendersonVPSell2,500$15.73$39,325.00View SEC Filing  
5/1/2014Stuart Cablemajor shareholderSell30,000$15.98$479,400.00View SEC Filing  
4/1/2014Lori HendersonVPSell2,500$18.74$46,850.00View SEC Filing  
4/1/2014Stuart Cablemajor shareholderSell30,000$18.52$555,600.00View SEC Filing  
2/27/2014Arthur RothDirectorSell5,000$15.95$79,750.00View SEC Filing  
2/27/2014Steven HagenSVPSell3,000$15.73$47,190.00View SEC Filing  
2/25/2014Steven HagenSVPSell2,500$15.19$37,975.00View SEC Filing  
2/24/2014Michael NolanCFOSell15,000$15.00$225,000.00View SEC Filing  
2/21/2014Steven HagenSVPSell1,500$14.87$22,305.00View SEC Filing  
2/19/2014Steven HagenSVPSell1,500$13.37$20,055.00View SEC Filing  
2/13/2014Stuart Cablemajor shareholderSell30,000$12.00$360,000.00View SEC Filing  
12/4/2013Steven HagenSVPSell2,500$10.93$27,325.00View SEC Filing  
12/3/2013William MarthDirectorBuy30,000$10.75$322,500.00View SEC Filing  
11/22/2013Steven HagenSVPSell2,300$11.55$26,565.00View SEC Filing  
11/22/2013William MarthDirectorBuy20,000$11.57$231,400.00View SEC Filing  
9/13/2013Stuart Cablemajor shareholderSell30,000$12.00$360,000.00View SEC Filing  
8/1/2013Stuart M CableMajor ShareholderSell30,000$12.53$375,900.00View SEC Filing  
7/1/2013Stuart M CableMajor ShareholderSell30,000$12.47$374,100.00View SEC Filing  
6/12/2013Stuart M CableMajor ShareholderSell30,000$12.00$360,000.00View SEC Filing  
5/22/2013Bruce J SargentSVPSell7,500$10.97$82,275.00View SEC Filing  
5/10/2013Steven R HagenSVPSell1,200$10.40$12,480.00View SEC Filing  
12/3/2012William S MarthDirectorBuy10,000$5.00$50,000.00View SEC Filing  
11/15/2012Ambra Thomas E Phd DCEOBuy10,000$3.80$38,000.00View SEC Filing  
8/9/2012Steven R HagenVPSell3,000$3.00$9,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Albany Molecular Research (NASDAQ:AMRI)
News IconSSCI Expands Biochemistry Services to Meet Growing Industry Demand (NASDAQ:AMRI) - February 16 at 3:34 PM logoAMRI Schedules Fourth Quarter and Full Year 2016 Earnings Release and Conference Call (NASDAQ:AMRI) - February 16 at 8:24 AM
News IconAlbany Molecular Research Inc AMRI Financial and Strategic SWOT Analysis Review [Updated: 19012017] Prices from USD $125 (NASDAQ:AMRI) - February 12 at 1:34 AM logoSSCI Launches Enhanced Web Site – Improves Customer Online Support Services (NASDAQ:AMRI) - February 8 at 3:45 PM logoA high through put mass spectrometer is coming to Buffalo (NASDAQ:AMRI) - February 8 at 3:45 PM logoAMRI Announces Strategic Alliance to Advance Mass Spectrometry Capabilities for Drug Discovery (NASDAQ:AMRI) - February 7 at 4:00 PM logoAlbany Molecular Research, Inc. – Value Analysis (NASDAQ:AMRI) : January 20, 2017 (NASDAQ:AMRI) - January 20 at 4:27 PM logoAlbany Molecular Research, Inc. breached its 50 day moving average in a Bullish Manner : AMRI-US : January 19, 2017 (NASDAQ:AMRI) - January 19 at 4:00 PM logoAlbany Molecular Research : Whitehouse Labs Increases Focus and Expertise In Extractables & Leachables (NASDAQ:AMRI) - January 18 at 4:04 PM
News IconSUNY Poly was planning $800 million biopharma center (NASDAQ:AMRI) - January 16 at 11:37 AM logoInteresting AMRI Put And Call Options For February 17th (NASDAQ:AMRI) - January 13 at 3:59 PM logoAlbany Molecular Research (AMRI) Presents At J.P. Morgan Healthcare Conference (NASDAQ:AMRI) - January 12 at 1:52 AM logoShort Interest Jumps 12.7% For AMRI (NASDAQ:AMRI) - December 28 at 3:29 PM logoCommit To Buy Albany Molecular Research At $12.50, Earn 9.9% Annualized Using Options (NASDAQ:AMRI) - December 27 at 3:50 PM logoALBANY MOLECULAR RESEARCH, INC. (NASDAQ:AMRI) Files An 8-K Other Events (NASDAQ:AMRI) - December 23 at 8:37 PM logoALBANY MOLECULAR RESEARCH INC Files SEC form 8-K, Other Events (NASDAQ:AMRI) - December 22 at 3:32 PM logoAMRI CEO to Present at 35th Annual J.P. Morgan Healthcare Conference (NASDAQ:AMRI) - December 13 at 3:35 PM logoIs Instructure Inc (INST) A Good Stock to Buy? (NASDAQ:AMRI) - December 12 at 8:41 PM logoAlbany Molecular Research : UAlbany Health Sciences campus awarded $4M grant (NASDAQ:AMRI) - December 12 at 7:29 AM logoTeewinot Life Sciences' Irish Subsidiary Full Spectrum Laboratories, Ltd. Secures a New U.S. Patent Covering … (NASDAQ:AMRI) - December 8 at 3:44 PM
News IconIs Albany Molecular Research, Inc. (AMRI) A Good Stock To Buy? (NASDAQ:AMRI) - December 5 at 5:14 PM logoAlbany Molecular Research, Inc. breached its 50 day moving average in a Bearish Manner : AMRI-US : December 2, 2016 (NASDAQ:AMRI) - December 2 at 10:40 AM
News IconAlbany Molecular Research inks API supply pact with Shire (NASDAQ:AMRI) - December 1 at 1:36 AM logoETFs with exposure to Albany Molecular Research, Inc. : November 28, 2016 (NASDAQ:AMRI) - November 29 at 1:48 PM logo7:45 am Albany Molecular announces API supply agreement with Shire (SHPG (NASDAQ:AMRI) - November 29 at 1:47 PM logoAMRI Announces API Supply Agreement with Shire (NASDAQ:AMRI) - November 29 at 1:47 PM logoAlbany Molecular Research, Inc. :AMRI-US: Earnings Analysis: Q3, 2016 By the Numbers : November 18, 2016 (NASDAQ:AMRI) - November 18 at 12:50 PM logoALBANY MOLECULAR RESEARCH INC Financials (NASDAQ:AMRI) - November 17 at 1:48 PM
News IconDrug Discovery Informatics Market size to exceed $6.5bn by 2023: Global Market Insights Inc. (NASDAQ:AMRI) - November 15 at 12:51 PM logoAMRI : to Present Two Posters at AAPS 2016 (NASDAQ:AMRI) - November 14 at 3:40 PM logoAMRI to Present Two Posters at AAPS 2016 (NASDAQ:AMRI) - November 14 at 11:26 AM logoETF’s with exposure to Albany Molecular Research, Inc. : November 11, 2016 (NASDAQ:AMRI) - November 11 at 12:51 PM logoAlbany Molecular Research, Inc. breached its 50 day moving average in a Bullish Manner : AMRI-US : November 10, 2016 (NASDAQ:AMRI) - November 10 at 1:57 PM logoALBANY MOLECULAR RESEARCH INC Files SEC form 10-Q, Quarterly Report (NASDAQ:AMRI) - November 9 at 10:02 PM logoAlbany Molecular Research, Inc. 2016 Q3 - Results - Earnings Call Slides (NASDAQ:AMRI) - November 8 at 8:59 PM logoEdited Transcript of AMRI earnings conference call or presentation 8-Nov-16 1:30pm GMT (NASDAQ:AMRI) - November 8 at 8:59 PM logoALBANY MOLECULAR RESEARCH INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements (NASDAQ:AMRI) - November 8 at 8:59 PM logoAlbany Molecular Research posts 3Q loss (NASDAQ:AMRI) - November 8 at 2:08 PM logoAlbany Molecular Research Becomes Oversold (AMRI) (NASDAQ:AMRI) - November 4 at 8:17 PM logoAlbany Molecular Research, Inc. breached its 50 day moving average in a Bearish Manner : AMRI-US : October 28, 2016 (NASDAQ:AMRI) - October 28 at 1:09 PM logoAMRI Schedules Third Quarter 2016 Earnings Release and Conference Call (NASDAQ:AMRI) - October 20 at 9:18 AM logoAMRI to Unveil Powerful Portfolio of APIs and Capabilities at CPhI in Barcelona (NASDAQ:AMRI) - October 3 at 3:26 PM logoAlbany Molecular Research, Inc. (NASDAQ:AMRI) under Investigation for Long-Term Investors (NASDAQ:AMRI) - September 29 at 3:42 PM logoALBANY MOLECULAR RESEARCH INC Files SEC form 8-K/A, Completion of Acquisition or Disposition of Assets, Financial Sta (NASDAQ:AMRI) - September 24 at 8:48 AM logoAlbany Molecular Research, Inc. – Value Analysis (NASDAQ:AMRI) : September 15, 2016 (NASDAQ:AMRI) - September 15 at 12:23 PM logoAlbany Molecular Research, Inc. breached its 50 day moving average in a Bearish Manner : AMRI-US : September 14, 2016 (NASDAQ:AMRI) - September 14 at 3:30 PM
News IconInvestor News: Investigation over possible Misconduct at Albany Molecular Research, Inc. (NASDAQ:AMRI) (NASDAQ:AMRI) - September 13 at 8:20 AM
News IconScienter and Securities Law; Federal Tort Claims Act; Tax Prosecution (NASDAQ:AMRI) - September 8 at 3:28 PM logoInvestigation for Long-Term Investors in Albany Molecular Research, Inc. (NASDAQ:AMRI) Announced (NASDAQ:AMRI) - August 30 at 11:29 AM logoAMRI CEO to Present at Morgan Stanley Global Healthcare Conference (NASDAQ:AMRI) - August 30 at 11:29 AM


What is Albany Molecular Research's stock symbol?

Albany Molecular Research trades on the NASDAQ under the ticker symbol "AMRI."

Where is Albany Molecular Research's stock going? Where will Albany Molecular Research's stock price be in 2017?

1 equities research analysts have issued 12 month price targets for Albany Molecular Research's stock. Their predictions range from $17.00 to $17.00. On average, they anticipate Albany Molecular Research's stock price to reach $17.00 in the next year.

When will Albany Molecular Research announce their earnings?

Albany Molecular Research is scheduled to release their next quarterly earnings announcement on Tuesday, February, 21st 2017.

Who owns Albany Molecular Research stock?

Albany Molecular Research's stock is owned by a number of of retail and institutional investors. Top institutional investors include Dimensional Fund Advisors LP (3.66%), Royce & Associates LP (3.10%), Loomis Sayles & Co. L P (1.57%), State Street Corp (1.23%), Netols Asset Management Inc. (0.97%) and Renaissance Technologies LLC (0.86%). Company insiders that own Albany Molecular Research stock include Ambra Constance M D, Ambra Thomas E Phd D, Anthony J Maddaluna, George Svokos, Kevin Oconnor, Lori M Henderson, Steven R Hagen, Stuart M Cable and William S Marth.

Who sold Albany Molecular Research stock? Who is selling Albany Molecular Research stock?

Albany Molecular Research's stock was sold by a variety of institutional investors in the last quarter, including Clough Capital Partners L P, Dimensional Fund Advisors LP, Allianz Asset Management AG, Netols Asset Management Inc., Loomis Sayles & Co. L P, Bessemer Group Inc. and NN Investment Partners Holdings N.V.. Company insiders that have sold Albany Molecular Research stock in the last year include Kevin Oconnor, Lori M Henderson and Steven R Hagen.

Who bought Albany Molecular Research stock? Who is buying Albany Molecular Research stock?

Albany Molecular Research's stock was bought by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Royce & Associates LP, State Street Corp, Denver Investment Advisors LLC, Ranger Investment Management L.P., GSA Capital Partners LLP, Renaissance Technologies LLC and Comerica Bank. Company insiders that have bought Albany Molecular Research stock in the last two years include Anthony J Maddaluna, George Svokos and William S Marth.

How do I buy Albany Molecular Research stock?

Shares of Albany Molecular Research can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Albany Molecular Research stock cost?

One share of Albany Molecular Research stock can currently be purchased for approximately $18.61.

Albany Molecular Research (NASDAQ:AMRI) Chart for Sunday, February, 19, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Albany Molecular Research (NASDAQ:AMRI)

Earnings History Chart

Earnings by Quarter for Albany Molecular Research (NASDAQ:AMRI)

Dividend History Chart

Dividend Payments by Quarter for Albany Molecular Research (NASDAQ:AMRI)

Last Updated on 2/19/2017 by Staff